Entries |
Document | Title | Date |
20080200405 | Drug Resistance Reversal In Neoplastic Disease - The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described. | 08-21-2008 |
20080227731 | BIPHENYL INHIBITORS OF CARBONYL REDUCTASE - Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising biphenyl compounds having two halogenated (or pseudo-halogenated) and/or hydroxylated, aryl groups that are linked by a bridging atom. The preferred composition of biphenyl compound(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately than the at least one anthracycline compound. Especially-preferred biphenyl compounds include triclosan, hexachlorophene, and dichlorophene. | 09-18-2008 |
20080249036 | Antagonist Against Tolerance to Anticancer Drugs - An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an anticancer drug; and cells useful in the development of an anticancer drug. The present invention provides a drug which inhibits the expression of an ABC transporter to thereby overcome resistance to anticancer drugs; cancer cells useful in screening such drugs; and an anticancer drug efficacious even against such a cancer as having acquired resistance to anticancer drugs. | 10-09-2008 |
20080255061 | Use of Phthalide Derivatives - Disclosed a class of phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent. The phthalide derivatives according to the invention can enhance the sensitivity of drug-resistance tumor cells against chemotherapy and decrease the drug-resistance of tumor cells 5-30 folder and enhance notably several chemotherapy agents-induced apoptosis of tumor cells | 10-16-2008 |
20080293647 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer - There is provided according to the invention a method of treating a patient with bladder cancer by administering a effective amount of a vitamin D compound in combination with one or more other antiproliferative agents. Also provided are uses of a vitamin D compound in combination with one or more other antiproliferative agents and compositions for use in the method. | 11-27-2008 |
20080293648 | Compositions and Methods for Cancer Treatment - This invention provides methods, novel formulations and kits to reduce the toxicity of anticancer drugs. Disclosed are therapeutics and treatment methods employing anticancer drags that exhibit a known toxicity, including, for example, adriamycin, campthothecin, and the like, chemically linked to a phosphonoformic acid partial ester resulting in a novel formulation that significantly decreases drug-related toxicity, enhances synergy with other chemotherapeutic drugs and provides increased efficacy against drug-resistant cancers. | 11-27-2008 |
20080318879 | Method for the Preparation of Polymeric Conjugates of Doxorubicin with Ph-Controlled Release of the Drug - A method for the preparation of polymeric conjugates of N-(2-hydroxypropyl)methacrylamide and a methacryloylaminoacylhydrazone of doxorubicin with pH-controlled release of the drug, comprising the following three steps of synthesis: a. preparation of a monomeric methacryloylaminoacylhydrazine, wherein the aminoacyl is derived from an amino acid or oligopeptide, by reaction of a methacryloyl halide with the respective peptide, amino acid, or a derivative thereof, and subsequent hydrazinolysis, b. synthesis of a polymeric precursor by direct copolymerization of N-(2-hydroxypropyl)methacrylamide with the methacryloylaminoacylhydrazine, and c. binding of doxorubicin to the polymeric precursor by reaction thereof with doxorubicin hydrochloride. | 12-25-2008 |
20080318880 | Neoadjuvant treatment of Breast Cancer - Neoadjuvant treatment of inflammatory or T3 to T4 breast cancer is carried out by administering to such patients a number of cycles of chemotherapy treatment in which DPPE first is administered followed by a combination of anthracyclines and taxanes. | 12-25-2008 |
20090005327 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC IN SUFFICIENCY AND HEART FAILURE THERAPY - The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent. | 01-01-2009 |
20090036390 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASES - Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma. | 02-05-2009 |
20090048187 | Chemopreventive, Anticancer and Anti-Inflammatory Effects of Pinoresinol-Rich Olives - The present invention relates to a composition and method for preventing and treating cancer and modulating cell proliferation using compositions extracted from pinoresinol-rich | 02-19-2009 |
20090062222 | Methods for Sensitizing Cancer Cells to Inhibitors - The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies. | 03-05-2009 |
20090105166 | Novel lapachone compounds and methods of use thereof - The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione). | 04-23-2009 |
20090105167 | Predicting responsiveness to cancer therapeutics - The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including salvage agents, to treat cancers such as ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments. | 04-23-2009 |
20090131344 | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives - This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. These orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthracyclines. | 05-21-2009 |
20090149399 | HETEROCYCLIC KINASE INHIBITORS - This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase. | 06-11-2009 |
20090186839 | Model for studying the role of genes in chemoresistance - The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth transformed cells and thereby reduce hyperproliferative conditions, such as cancer progression, in select patient populations having particular tumor genotypes. The invention also provides methods which target translation initiation controls in growth-transformed cells, such as tumor subtypes with altered expression of a gene activity, including the human akt, bcl-2, eIF4E, eIF4A or PTEN activities, to restore drug sensitivity in vivo in a genotype selective manner. In one aspect, the inhibitors of translation initiation of the invention are rocaglates, i.e., cyclopenta[b]benzofurons, which increases chemosensitivity or diminishes or reverses chemoresistance either alone or in combination, additively or synergistically, with other agents that alter growth or death. Preferably, the rocaglate is silvestrol, which is used alone or in combination with doxorubicin to reverses chemoresistance in PTEN-deficient lymphomas or eIF4E-over-expressing lymphomas and to promote cancer remission. | 07-23-2009 |
20090215709 | Methylation markers for diagnosis and treatment of cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 08-27-2009 |
20090298785 | Method for Treating Ocular Cancer - It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided. | 12-03-2009 |
20090298786 | METHODS OF TREATING VIRAL INFECTIONS WITH ANTHRACYCLINE ANTIBIOTICS - A method of treating hepatitis C viral infection or viremia in a patient by administering to the patient an anti-hepatitis C virally effective amount of a compound of Formula 1 or Formula 2. A method for inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis C viral NS3 protease inhibiting amount of: a compound of Formula 1 or Formula 2. A pharmaceutical composition exhibiting an antihelicase activity containing at least a pharmaceutically-acceptable carrier, diluent or excipient, and a compound of Formula 1 or Formula 2. The pharmaceutical composition may additionally contain a second compound of Formula 1 or Formula 2; epidoxorubicin, doxorubicin, epidaunorubicin, or daunorubicin; and/or another antiviral agent. | 12-03-2009 |
20090306004 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION - A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly, GlyPheGly, GlyPheLeuGly and GlyLeuPheGly, and a method of its preparation. | 12-10-2009 |
20090312277 | Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent - The present invention provides a composition and method for increasing sensitivity of a cancer cell and to reverse or prevent resistance to a cytotoxic agent. The composition includes an inhibiting agent and, optionally, a cytotoxic agent. The inhibiting agent is present in a sub-lethal dose with respect to the cancer cell in the absence of the cytotoxic agent. | 12-17-2009 |
20090325893 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME - Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | 12-31-2009 |
20090325894 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES - The present invention provides aminoside tetracyclic anthraquinones represented by formula (I) or formula (II), wherein the peptides are introduced to connect tetracyclic anthraquinones and fatty acid saturated or unsaturated in order to make the anticancer agents to be absorbed and released selectively; meanwhile some water-solubility groups are also introduced into the branched chain, aminosaccharide and tetracyclic moiety of the compounds to improve the water-solubility. The present invention also provides the preparative method and the use thereof as pharmaceutically active components for treating the diseases cured by aminoside tetracyclic anthraquinone, for example cancer, such as intestines, liver, gastric, breast, lung, ovary, prostate, brain glioma, lymph, skin, pigment, thyroid gland, multiple bone marrow cancer and leukemia. | 12-31-2009 |
20100009926 | PH-SENSITIVE POLYMERIC MICELLES FOR DRUG DELIVERY - Mixed micelles containing poly(L-histidine-co-phenylalanine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed. | 01-14-2010 |
20100016249 | CANCER SENSITIZER COMPRISING GLUCOSAMINE, GLUCOSAMINE DERIVATIVES OR SALTS THEREOF - Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy. | 01-21-2010 |
20100022466 | THERMALLY-TARGETED DELIVERY OF MEDICAMENTS INCLUDING DOXORUBICIN - Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat protein, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer and a cysteine residue conjugated to therapeutic such as doxorubicin, or a analog thereof. | 01-28-2010 |
20100041619 | Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders - The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative. | 02-18-2010 |
20100048499 | BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE - The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor. | 02-25-2010 |
20100069316 | TREATMENT FOR MULTIPLE MYELOMA - The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I: | 03-18-2010 |
20100069317 | CRYSTALLINE NEMORUBICIN HYDROCHLORIDE - This invention relates to a novel crystalline polymorphic form of nemorubicin hydrochloride dihydrate, useful for the preparation of pharmaceutical composition for the treatment of tumors. A process for preparing this novel polymorphic form, named form A, is within the scope of the present invention. | 03-18-2010 |
20100087385 | APPLICATION OF GLYCYRRHIZIC ACID AND ITS BREAKDOWN PRODUCT GLYCYRRHETINIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The application of glycyrrhizic acid and its breakdown product glycyrrhetinic acid for the treatment of inflammatory bowel disease is disclosed. Glycyrrhizic acid or glycyrrhetinic acid and glycyrrhizinate or glycyrrhetate can treat inflammatory bowel disease by inhibiting inflammatory reactions and antioxidation. | 04-08-2010 |
20100099637 | USE OF CYCLOARTANE COMPOUNDS FOR TREATING ARTHRITIS - A method of treating a disease associated with cartilage defect in a subject in need thereof by administering to the subject an effectively amount of a cycloartane compound of Formula (I). | 04-22-2010 |
20100099638 | IMMUNOCOMPETENT XENOGRAFT MODEL - The teachings are directed to an immunocompetent xenograft model. The model comprises an immunodeficient animal modified to have a reconstituted immune system, wherein a xenograft is transplanted in the animal and allowed to establish for an establishment period of at least about 10 days. The xenograft simulates a tissue in a subject in need of a treatment. In these embodiments, the reconstituted immune system is created after the establishment period, and is created by administering a total number of T-cells to the animal. The total number of T-cells consists of a preselected number of responsive T-cells, a preselected number of non-responsive T-cells, and a preselected ratio of responsive T-cells to total T-cells. The preselected number of responsive T-cells simulates a number of responsive T-cells in the subject, and the ratio of the number of responsive T-cells to total T-cells ranges from about 1:100,000 to about 30:100,000. | 04-22-2010 |
20100099639 | W/O/W EMULSION COMPOSITION - The present invention provides a W/O/W multiple emulsion composition composed of an internal aqueous phase, an oil phase, and an external aqueous phase, the internal aqueous phase containing an ionic physiologically active substance and a physiologically acceptable compound having a molecular weight of 1,000 or less and generating a polyvalent counterion with two or more valencies for the ionic physiologically active substance. The W/O/W emulsion composition of the present invention not only can stably encapsulate a useful substance in its internal aqueous phase at a high encapsulation ratio, but also has high safety. | 04-22-2010 |
20100099640 | TISSUE DEGENERATION PROTECTION - The present invention provides isolated or essentially pure diterpenoic tetrahydropyran, such as steviol-19-glucuronide, steviol, stevioside and rebaudioside processes for obtaining the same and methods for obtaining stable pharmaceutically acceptable salts of the same for use of such compounds or compositions in a treatment of cardiovascular disorders or vascular disease or for the manufacture of medicaments to treat a condition of a cardiovascular disorder or vascular disease. | 04-22-2010 |
20100113377 | Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds - Methods for treating or preventing cardiomyopathy in a subject by administering an al adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided. | 05-06-2010 |
20100113378 | Compositions and Methods for Treating and Preventing Cancer Using Analogs of Vitamin D - Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer. | 05-06-2010 |
20100144659 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer. | 06-10-2010 |
20100144660 | USE OF N,N-DIETHYL-2-[-4-(PHENYLMETHYL)-PHENOXY]ETHANAMINE MONOHYDROCHLORIDE (DPPE) IN CANCER THEREAPY - The present invention provides for the use of N,N-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (DPPE) in cancer therapy. DPPE is used in the treatment of patients having, or suspected of having, an aggressive cancer. The present invention further provides for the use of DPPE in the treatment of a patient suspected of having an existing cancer, wherein the use follows a surgery for treatment of a primary cancer that is estrogen-receptor negative. Also provided are pharmaceutical compositions comprising DPPE for use in the treatment of patients having, or suspected of having, an aggressive cancer and pharmaceutical kits comprising such compositions. | 06-10-2010 |
20100160246 | MICROSPHERES FOR TREATMENT OF BRAIN TUMORS - There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided. | 06-24-2010 |
20100168044 | SUPERPARAMAGNETIC NANOPARTICLE ENCAPSULATED WITH STIMULI RESPONSIVE POLYMER FOR DRUG DELIVERY - The current invention is a novel superparamagnetic site-targeting nanoparticle comprising superparamagnetic nanoparticles encapsulated with a smart polymer. The superparamagnetic site-targeting nanoparticle comprises a functionalized superparamagnetic core that is conjugated with a therapeutic agent and then encapsulated with a smart polymer. The smart polymer can be any polymer that exhibits a reversible conformational or physio-chemical change in response to an external stimulus or stimuli. | 07-01-2010 |
20100173862 | INJECTABLE, INJECTION SOLUTION, AND INJECTION KIT PREPARATION - Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide. | 07-08-2010 |
20100190736 | MORPHOLINYL ANTHRACYCLINE DERIVATIVE COMBINED WITH PROTEIN KINASE INHIBITORS - The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. | 07-29-2010 |
20100227831 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - A novel composition of a phosphonoformic acid partial ester chemically linked to an anticancer compound of the general formula: | 09-09-2010 |
20100234314 | IDARUBICIN FOR THE TREATMENT OF LYMPHOMA IN A DOG - The present invention relates to a method of treating a lymphoma in a dog comprising administering to a dog in need of such treatment a therapeutically effective amount of idarubicin or a pharmaceutically acceptable salt thereof. | 09-16-2010 |
20100234315 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND BEHAVIORAL DISORDERS - In one aspect, the present invention provides methods that comprise administering to a patient an active agent that comprises one or more of protoveratrine A, protoveratrine B, cevadine, veratramine and veratrosine in an amount that is effective to lessen the severity or occurrence of at least one symptom indicative of the disorder. | 09-16-2010 |
20100273729 | Compositions Comprising Compounds Of Natural Origin For Damaged Skin - The present invention relates to a skin-protecting composition for the damaged skin, comprising glycyrrhizin, quercetin, rosmarinic acid, madecassic acid, chamazulene, bicalein and emodin. The composition of the present invention has all of excellent antioxidant, anti-inflammatory, wound-healing and moisturizing effects, thereby being widely used in medicine, cosmetic material or the like for the purpose of protecting the easily infectable, damaged and dried skin. | 10-28-2010 |
20100279963 | DICARBONYL DERIVATIVES AND METHODS OF USE - Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents. | 11-04-2010 |
20100279964 | Angular Pyranocoumarins, Process for Preparation and Uses Thereof - The present invention relates to methods of using 3′,4′-aromatic acyloxy substituted 7,8-pyranocoumarins compounds in reversing P-glycoprotein overexpression mediated multidrug resistance in cancer cells including uses in treating cancers. | 11-04-2010 |
20100305057 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER - A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination. | 12-02-2010 |
20100305058 | INDIVIDUALIZED CANCER TREATMENTS - The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments. | 12-02-2010 |
20100323979 | METHODS AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF ANEUPLOID CELLS - The present invention relates, in part, to the use of AMP kinase agonists to reduce or inhibit the proliferation of aneuploid cells. The invention is also directed to the use AMP kinase agonists to reduce or inhibit the proliferation of solid tumors characterized by aneuploidy in an individual. | 12-23-2010 |
20100331273 | SELF-ASSEMBLING COMPLEX FOR TARGETING CHEMICAL AGENTS TO CELLS - The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs. | 12-30-2010 |
20110009353 | TARGETING CDK4 AND CDK6 IN CANCER THERAPY - The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies. | 01-13-2011 |
20110015144 | ADMINISTRATION METHOD PROPOSING DEVICE - There was no device that proposes a method for administrating anti-cancer drugs according to each of cancer types. | 01-20-2011 |
20110021451 | LIPID TUMOUR PROFILE - We describe a method of generating a classification model capable of distinguishing between two biological states, the method comprising the steps of: (a) providing a training dataset, X, comprising concentrations of a plurality of lipids in a biological sample in a first state and a biological sample in a second state; (b) subjecting the training dataset X to Principal Components Analysis (PCA), in which the PCA analysis generates a transformation matrix, C, and a transformed dataset, Y | 01-27-2011 |
20110021452 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS - The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said preparation is useful as a chemotherapeutic agent for cancers. | 01-27-2011 |
20110053878 | ACID-SENSITIVE LINKERS FOR DRUG DELIVERY - The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods. | 03-03-2011 |
20110053879 | PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER - A method for treatment of lung cancer comprising administration of picoplatin and amrubicin, or comprising radiation therapy and picoplatin is provided. A use of picoplatin in conjunction with amrubicin for treatment of lung cancer is provided. The lung cancer can be SCLC or NSCLC. The cancer can be resistant or refractory to treatment or that progresses following cessation of first-line organoplatinum chemotherapy. The treatment can include the administration of picoplatin and amrubicin, optionally in conjunction with a regimen of best supportive care. Multiple doses of the drug or drug combination can be administered. | 03-03-2011 |
20110071099 | Cationic Ceramides, And Analogs Thereof, And Their Use For Preventing Or Treating Cancer - The present invention relates to cationic ceramides, their dihydro-analogs and aromatic analogs and their derivatives, comprising a pyridinium group. Also provided are methods for making cationic ceramides comprising a pyridinium group, and their use for treating or preventing diseases associated with cell overproliferation and sphingolipid signal transduction, such as cancer, inflammation, and stenosis. The compounds are also useful as mitochondritropic agents that are localized to mitochondria carrying with them chemical cargoes, such as drugs, or signaling molecules, such as fluorophores for probing organelle structure and functions. | 03-24-2011 |
20110105422 | USE OF G-RICH OLIGONUCLEOTIDES FOR TREATING NEOPLASTIC DISEASES - The invention relates to methods of treating patients (either adult or paediatric) with tumours using G rich oligonucleotides. In embodiments of the invention, methods of treating patients with tumours using a combination of G rich oligonucleotides and a chemotherapeutic agent are provided. There are also provided pharmaceutical compositions and kits for use in the methods of the invention. | 05-05-2011 |
20110105423 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF - The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded RNA viruses, such as influenza virus, in substrates for virus propagation (e.g., tissue culture). The invention also relates to the use of compounds that decrease virus replication as antiviral agents. The invention further relates to methods for identifying compounds that modulate the replication of negative-sense, single-stranded RNA viruses, in particular, influenza virus. | 05-05-2011 |
20110118199 | USE OF CNS PENETRATING ANTICANCER COMPOUNDS FOR THE TREATMENT OF PROTOZOAL DISEASES - The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria. | 05-19-2011 |
20110118200 | A PEGYLATED AND FATTY ACID GRAFTED CHITOSAN OLIGOSACCHARIDE, SYNTHESIS METHOD AND APPLICATION FOR DRUG DELIVERY SYSTEM - The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition. | 05-19-2011 |
20110144047 | COMBINED METHOD FOR PREDICTING THE RESPONSE TO AN ANTI-CANCER THERAPY - The invention provides methods for predicting the response to a topoisomerase Ilα inhibitor therapy in an individual having cancer, wherein the methods comprise the steps of determining TIMP-I DNA aberration/TIMP-1 protein aberration in combination with determining DNA aberration in TOP2A/HER2 amplicon on chromosome 17q21 including TOP2A and HER2 or aberrations of TOP2A and ErbB2 protein expression. Further provided are methods of treating cancer by using said topoisomerase Ilα inhibitor therapy. The invention also comprises a kit for the application of the methods for predicting the response to a topoisomerase Ilα inhibitor therapy in an individual having cancer. | 06-16-2011 |
20110152212 | Aqueous Formulations - A method of preparing an aqueous formulation of an active material and such a formulation per se are described, wherein the active material has a very low solubility in water. The method may involve contacting active material in solid form with an optionally cross-linked water soluble polymer. The water soluble polymer is preferably a polyvinyl polymer with polyvinylalcohol being preferred. The polymer is optionally cross-linked. The method and formulation may be of particular utility in delivery of anti-cancer drugs or drugs via a pulmonary route. | 06-23-2011 |
20110183931 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 07-28-2011 |
20110207685 | Oral Formulations of Chemotherapeutic Agents - The present invention is directed to new oral formulations of chemotherapeutic agents, their process of preparation as well as their therapeutic uses. More specifically, said invention is related to nanoparticles comprising at least one chemotherapeutic agents as an active ingredient, at least one polymer and at least one cyclic oligosaccharide capable of complexing said camptothecin derivative, said nanoparticles being for therapeutic oral administration. | 08-25-2011 |
20110207686 | POLYSACCHARIDE-AND POLYPEPTIDE-BASED BLOCK COPOLYMERS, VESICLES CONSTITUTED BY THESE COPOLYMERS AND USE THEREOF - The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, and to the use thereof for encapsulation, transport, vectorization, and targeting of molecules of interest. | 08-25-2011 |
20110212911 | TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS - The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular. | 09-01-2011 |
20110224161 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF - The present invention relates to tetracyclic anthraquinone antibiotic derivatives with anticancer activity. The tetracyclic anthraquinone antibiotic derivatives as provided in the present invention have the same or higher activity than that of the known drugs such as doxorubicin, daunorubicin and the like in the cellular level while having better tolerance than that of doxorubicin and daunorubicin in the animal body. | 09-15-2011 |
20110237535 | Use of Induced Pluripotent Cells and other Cells for Screening Compound Libraries - The invention provides methods for screening test compounds or toxins for effects on cells. The invention also provides methods for determining frequency, amplitude and kinetic profiles of cells. | 09-29-2011 |
20110263522 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES - Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described. | 10-27-2011 |
20110275585 | TARGETED DELIVERY OF DRUGS, THERAPEUTIC NUCLEIC ACIDS AND FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA INTACT KILLED BACTERIAL CELLS - A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands. | 11-10-2011 |
20110281813 | METHOD OF TREATING C-KIT POSITIVE RELAPSED ACUTE MYELOID LEUKEMIA - The present invention relates to a method of treating c-kit positive relapsed acute myeloid leukemia (AML) in a human patient population using a combination comprising a c-kit inhibitor, daunorubicin and cytarabine. | 11-17-2011 |
20110281814 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER - The invention relates to methods and compositions for treating a subject afflicted with breast cancer using a CX-CR4 antagonist and optionally in combination with a chemotherapeutic agent. | 11-17-2011 |
20110301108 | MATERIALS AND METHODS FOR SENSITIZING MULTIDRUG RESISTANT CELLS - Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant caner cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins. They are not toxic to animals at levels at which they effect the activity of ABCG2 expressed in multi-drug resistant cancer lines. | 12-08-2011 |
20110312907 | POLYMORPHISMS PREDICTIVE OF ANTHRACYCLINE- INDUCED CARDIOTOXICITY - Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity. | 12-22-2011 |
20110319353 | TREATMENT FOR SPINAL MUSCULAR ATROPHY - A method of treating spinal muscular atrophy. The method includes administering an effective amount of composition including a sodium-proton exchanger inhibitor and a pharmaceutically acceptable carrier or salt, to a subject with spinal muscular atrophy to ameliorate a symptom of spinal muscular atrophy. | 12-29-2011 |
20110319354 | Combination Cancer Therapy with an AKT Inhibitor and Other Anticancer Agents - The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors. | 12-29-2011 |
20120022011 | HSP90 INHIBITORS WITH MODIFIED TOXICITY - The invention provides purified 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders. | 01-26-2012 |
20120028917 | Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methy- l-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer - The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl) -1-phthalazinamine, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject. | 02-02-2012 |
20120035126 | Compounds For Reducing Drug Resistance And Uses Thereof - This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds. | 02-09-2012 |
20120065154 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof - This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of making derivatives and analogs of SDR inhibitors and methods of use thereof. | 03-15-2012 |
20120077768 | STABILIZED AND LYOPHILIZED FORMULATION OF ANTHRACYCLINE COMPOUNDS - The present invention provides a lyophilized amrubicin formulation and a process thereof. In the process, the concentration of the aqueous solution before lyophilization is controlled to about 7.5 mg(potency)/mL or more. Thus, the formulation decreases the production of desaccharified compound and is stable to storage for a long period. The formulation is useful as a cancer chemotherapeutic agent. | 03-29-2012 |
20120129797 | BIODEGRADABLE STEALTH POLYMERIC PARTICLES FABRICATED USING THE MACROMONOMER APPROACH BY FREE RADICAL DISPERSION POLYMERIZATION - The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monmer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent. Another embodiment of the present invention is a polymer particle comprising, a crosslinked copolymer comprises structures represented by Formulas (I), (II), and (III), where Formulas (I), (II) and (III) are defined in the specification. Yet other embodiments of the present invention include a method of preparing a methacrylate terminated macromonomer, a method of preparing a crosslinking agent, and a method of preparing a therapeutic agent loaded nanosphere by dispersion polymerization. | 05-24-2012 |
20120129798 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS - The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent (the crosslinking agent may be absent in the case of non-crosslinked particles). The present invention is still further directed to a polymer particle comprising a crosslinked copolymer, where the crosslinked copolymer includes structures represented by Formulas (I), (II), and (III), as defined in the specification. Other embodiments of the present invention also include methods of manufacturing polymer particles. | 05-24-2012 |
20120135944 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 05-31-2012 |
20120142623 | Compositions And Methods For Predicting Inhibitors Of Protein Targets - Compositions and methods are provided for predicting inhibitors of protein targets related to treatment of infectious disease, for example, bacterial, viral, or parasitic diseases. Methods are provided for predicting inhibitors of protein targets related to treatment infectious disease, for example, microbial disease, utilizing a docking with dynamics protocol to identify inhibitors, or utilizing a protein structure energy function to identify peptide or peptidomimetic inhibitors. | 06-07-2012 |
20120142624 | AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY - Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer. | 06-07-2012 |
20120184500 | STEVIA EXTRACT OR STEVIOL FOR HAIR CARE - This invention relates to the use of an oral composition comprising | 07-19-2012 |
20120202760 | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate - This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs. | 08-09-2012 |
20120202761 | Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt - This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse effects and toxicity in noncancerous tissues. Daunorubicin orotate provides a safer treatment for specific types of leukemias and neuroblastomas in adults and in pediatric patients. | 08-09-2012 |
20120208780 | HYBRID NANOMATERIALS CONSISTING OF PSEUDOROTAXANES, PSEUDOPOLYROTAXANES, ROTAXANES, POLYROTAXANES, NANOPARTICLES AND QUANTUM DOTS - This invention provides the synthesis of biocompatible and high functional hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots (QDs). The molecular self-assembly of hybrid nanomaterials lead to the formation of nano-objects with different shapes such as core-shell, spindle-like or necklaces. Due to their well-defined molecular self-assemblies, carbohydrate backbone, high functionality and several types of functional groups together with the high luminescence yield, thermal and physical properties and synthesized hybrid nanostructures were recognized as promising candidates for a wide range of applications. | 08-16-2012 |
20120214757 | Methods and Compositions for Treating Cancer Using Proteasome Inhibitors - The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent. | 08-23-2012 |
20120214758 | TYROSINE KINASE RECEPTOR ANTAGONISTS AND METHODS OF TREATMENT FOR PANCREATIC CANCER - A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine. | 08-23-2012 |
20120232027 | CROSSLINKING BRANCHED MOLECULE THROUGH THIOL-DISULFIDE EXCHANGE TO FORM HYDROGEL - In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the solution is adjusted to initiate thiol-disulfide exchange in the precursor, thus crosslinking the precursor through disulfide bonds formed by thiol-disulfide exchange. After the precursor is sufficiently crosslinked to form a hydrogel, the pH in the solution is adjusted to inhibit further thiol-disulfide exchange in the hydrogel. Further, a hydrogel matrix may comprise a polymer substantially crosslinked through disulfide bonds. The polymer may comprise a hydrophobic poly(amido amine) core and an amino-functionalized hydrophilic shell. | 09-13-2012 |
20120238518 | DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER - Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N | 09-20-2012 |
20120252748 | METHODS AND COMPOSITIONS FOR DETERMINING THE RESPONSIVENESS OF CANCER THERAPEUTICS - The present invention relates to methods for predicting the responsiveness of a patient to a breast cancer treatment regimen by assaying a biological sample to determine the level of expression of the long-chain fatty acyl-CoA synthetase 4 (ACSL4) in the biological sample. The present invention also provides ACSL4 inhibitors and uses of ACSL4 inhibitors as adjuvant therapies in breast cancer treatment regimens. | 10-04-2012 |
20120252749 | Methods of Treating Cancer with Glut Inhibitors - Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided. | 10-04-2012 |
20120277176 | Protein Arginine Deiminase Inhibitors as Novel Therapeutics for Rheumatoid Arthritis and Cancer - In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm. | 11-01-2012 |
20120283206 | Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. - A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease. | 11-08-2012 |
20120295861 | Combination Therapy With Organic Arsenicals - The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent. | 11-22-2012 |
20120302516 | NANOPARTICLES FOR DRUG DELIVERY - The invention provides magnetic nanoparticles comprising a core, wherein the nanoparticles comprise at least one therapeutic agent linked to the core via a hydrazone linkage or via an oxime ether linkage, methods for making said nanoparticles, and methods for using said nanoparticles. | 11-29-2012 |
20120309704 | COMPOSITIONS FOR TREATMENT OF CHEMORESISTANT AND/OR POTENTIALLY CHEMORESISTANT LEUKAEMIAS - This description applies to pharmaceutical compositions comprising a mixture comprising one or more hERG1 channel blockers in combination with one or more compounds for anticancer therapy for use in the treatment of chemoresistant or potentially chemoresistant leukaemias and in vitro systems for the screening of substances suitable for use in the treatment of chemoresistant or potentially chemoresistant leukaemias. | 12-06-2012 |
20120329744 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same - Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | 12-27-2012 |
20130012465 | BIBW 2992 FOR USE IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER - The present invention relates to a method of treating patients suffering from triple negative breast cancer comprising administration of an effective amount of the irreversible EGFR/HER1 and HER2 inhibitor BIBW 2992 (1) to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent (2), in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery. | 01-10-2013 |
20130012466 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE - Colchicine neoglycosides, method for their synthesis and methods for their use are disclosed. The invention provides analogs of colchicine glycosylated to include a sugar moiety on a colchicine scaffold that is generally unglycosylated in nature. The colchicine neoglycosides disclosed herein are shown to have cytotoxic effects equivalent to at least the known cytotoxins paclitaxel and doxorubicin. Further, the neoglycosides disclosed according to the invention have physiologic effects not previously recognized in the alkaloid family that includes colchicine but recognized in other cytotoxic drug families such as the taxanes which act by stabilizing tubulin formation. | 01-10-2013 |
20130029926 | COMPOSITIONS AND METHODS FOR DETERMING CANCER SUSCEPTIBILITY - The invention generally relates to a molecular classification of disease and particularly to molecular markers for cancer susceptibility and methods of use thereof. More specifically, the invention relates to the determination, screening, or classification of an individual's genetic risk for breast and ovarian cancer susceptibility. | 01-31-2013 |
20130029927 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 01-31-2013 |
20130029928 | COMPOSITIONS COMPRISING PERFLUOROOCTANOIC ACID - There is provided compositions comprising perfluorooctanoic acid (PFOA) or a salt, derivative or variant thereof. There is also provided uses, methods therapeutic systems and combination therapies relating to PFOA. | 01-31-2013 |
20130040904 | METHOD OF TREATMENT USING ALPHA-1-ADRENERGIC AGONIST COMPOUNDS - Methods for treating or preventing cardiomyopathy in a subject by administering an α1 adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided. | 02-14-2013 |
20130040905 | Combination Of Drugs With Protein-Binding Prodrugs - The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination. | 02-14-2013 |
20130059806 | EPIGENETIC CO-REPRESSORS OF THE GAMMA-GLOBIN GENE AND METHODS OF USING SAME - This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene. | 03-07-2013 |
20130090297 | NUTRITIONAL COMPOSITIONS - Compositions for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia, and methods of administering such compositions. | 04-11-2013 |
20130102553 | Therapeutic Strategies For Prevention And Treatment Of Alzheimer's Disease - The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease. | 04-25-2013 |
20130109643 | METABOLIC INHIBITOR AGAINST TUMORS HAVING AN IDH MUTATION | 05-02-2013 |
20130131001 | Epirubicin Derivatives - Disclosed are compounds represented by formula (I), pharmaceutically acceptable salts thereof, solvates thereof, and solvates of the pharmaceutically acceptable salts thereof, | 05-23-2013 |
20130131002 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - The present invention relates to methods of treating pulmonary hypertension in a subject including administering to the subject a therapeutically effective dose of at least one anthracycline. | 05-23-2013 |
20130137650 | METHODS OF TREATMENT USING COMBINATION THERAPY - Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof. | 05-30-2013 |
20130172283 | LYOPHILIZED FORMULATION OF PECTIN-ADRIAMYCIN CONJUGATE AND PREPARATION METHOD THEREOF - The invention belongs to the pharmaceutical field, and particularly relates to a lyophilized formulation of pectin-adriamycin conjugate and a preparation method thereof. In order to solve insolubility problem of the pectin-adriamycin conjugate (hereinafter referred to as PAC), improve bioavailability and facilitate preparation, the inventor prepared the PAC into a nanosuspension. However, as long-term stability of the nanosuspension is poor, the inventor proposed to prepare the nanosuspension into a lyophilized formulation, that is, an insoluble pectin-adriamycin conjugate is prepared into a suspension or nanosuspension, and a lyophilized support agent is added to the suspension for lyophilization treatment to prepare the lyophilized formulation. Lyophilized products prepared from the nanosuspension are characterized by enhanced stability of nano-particle size and enhanced stability of drug loading rate, which provides a new solution for clinical application of the PAC. | 07-04-2013 |
20130178436 | COMPOSITION FOR PREVENTING, IMPROVING, OR TREATING RENAL DISEASE INCLUDING MAILLARD BROWNING REACTION PRODUCTS OF PANAX SPECIES PLANT EXTRACT - A composition for preventing, improving, or treating renal diseases, the composition including as an active ingredient a Maillard browning reaction product obtained by reacting ginsenoside Re, an extract of | 07-11-2013 |
20130178437 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION - The present invention relates to hydroxyalkyl starch (HAS) conjugates and to a method for preparing the hydroxyalkyl starch (HAS) conjugates, the hydroxyalkyl starch (HAS) conjugates comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according the following formula HAS′(-M) | 07-11-2013 |
20130190261 | COMPOSITION COMPRISING XANTHOCERAS SORBIFOLIA EXTRACTS, COMPOUNDS ISOLATED FROM SAME, METHODS FOR PREPARING SAME AND USES THEREOF - This invention provides compositions, methods and process of producing extracts from | 07-25-2013 |
20130190262 | Compounds Useful for Inhibiting Chk1 - The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer. | 07-25-2013 |
20130210756 | PHEOPHORBIDE-alpha CONJUGATES AND THEIR USES - The present invention relates to a pheophorbide-α conjugate or its salt, solvate or hydrate. The pheophorbide-α conjugate of the present invention exhibiting fluorescence upon its introduction into cells and degradation inhibits the survival of various cancer cells. Especially, the conjugate of pheophorbide-α and doxorubicin shows higher fluorescence intensity at lower pH (cancer environment). Therefore, the present composition for photodynamic therapy (PDT) of cancers is also very useful in detecting cancers. Interestingly, the anticancer effects of the present composition are dually exerted with help of both the photosensitizer and the anticancer drug of the present conjugates. | 08-15-2013 |
20130244963 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMIN- O)PYRIMIDINE-5-CARBOXAMIDE - The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia. | 09-19-2013 |
20130274217 | Controlled Release Formulations for the Delivery of HIF-1 Inhibitors - Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD. | 10-17-2013 |
20130281394 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. | 10-24-2013 |
20130288991 | BLOCK COPOLYMERS FOR STABLE MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 10-31-2013 |
20130303474 | COMPOSITION FOR ENHANCING IMMUNITY CONTAINING COMPOUNDS REPRESENTED BY CHEMICAL FORMULAS 1-8 OR SOPHORA FLAVESCENS EXTRACT AS ACTIVE INGREDIENT - The present invention relates to a composition for enhancing immunity through inducing the expression of interferon-β comprising a compound represented by Formulas 1 to 8, or | 11-14-2013 |
20130324490 | BIODEGRADABLE, WATER SOLUBLE AND PH RESPONSIVE POLY(ORGANO)PHOSPHAZENES - The present invention relates in general to the field of targeted drug delivery of anti-cancer drugs. More precisely, the present invention concerns polymer drug conjugates, namely, conjugates of poly(organo)phosphazenes and anti-cancer drugs, wherein the conjugates are suitable to selectively release anti-cancer drugs in tumor tissue. In addition, the present invention relates to a method for manufacturing such poly(organo)phosphazene molecule conjugates, to poly(organo)phosphazene molecule conjugates for use in medicine, in particular, to poly(organo)phosphazene molecule conjugates for use in the treatment of cancer, and to pharmaceutical compositions comprising such poly(organo)phosphazene molecule conjugates. | 12-05-2013 |
20130338091 | HUMAN BetaV-TUBULIN ANTIBODY AND METHODS OF USE - Antibodies to human βV-tubulin, fragments thereof, and compositions comprising such are provided. Diagnostic, prognostic and identification methods employing such antibodies or fragments thereof are also provided. | 12-19-2013 |
20130338092 | COMPOUNDS AND METHODS FOR TARGETING LEUKEMIC STEM CELLS - This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia. | 12-19-2013 |
20130345161 | Methods of Treating Breast Cancer With Taxane Therapy - The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including a taxane or a taxane derivative. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including a taxane or a taxane derivative and administering the therapy in subjects when it is found that a taxane or a taxane derivative is likely to be effective. | 12-26-2013 |
20140005134 | GPBP-1 inhibition and its therapeutic use | 01-02-2014 |
20140011760 | Novel Polymers and the Preparation of Nanogel Drug Cocktails - Methods for forming, modifying, and drug loading of a copolymer are provided, along with the resulting products. The method can include polymerizing 2-(pyridin-2-yldisulfanyl)ethyl acrylate with poly(ethylene glycol)methacrylate via free radical polymerization to form the copolymer. The molar ratio of 2-(pyridin-2-yldisulfanyl)ethyl acrylate to poly(ethylene glycol)methacrylate is about 100:1 to about 1:100. After polymerizing, the copolymer can be reacted with a thiol monomer that contains a carbon-bonded sulfhydryl to modify end groups on a first portion of the 2-(pyridin-2-yldisulfanyl)ethyl acrylate repeating units. Thereafter, the copolymer can be crosslinked, and a drug can then be loaded into the crosslinked copolymer. | 01-09-2014 |
20140024610 | NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC ANTITUMORAL DRUG - The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticules loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticules by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment. | 01-23-2014 |
20140057861 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLINE INDUCED CARDIOTOXICITY - The invention features methods and compositions feature lapatinib and/or rapamycin for treating or preventing a cardiac condition induced by anthracycline treatment. | 02-27-2014 |
20140057862 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF - Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | 02-27-2014 |
20140066393 | METHOD OF SELECTING CANCER PATIENTS FOR ANTI-ANGIOGENESIS THERAPY IN COMBINATION WITH CHEMOTHERAPY - What is described is a method for identifying a cancer patient that is amenable to anti-angiogenesis therapy in combination with chemotherapy for longer overall survival and/or progression-free survival by measuring the status of tumor cell HER2 expression, p53 expression, and apoptosis or endothelial cell CD31 expression in a tumor sample obtained from the patient prior to treatment. Bevacizumab, an antibody to vascular endothelial growth factor, is a preferred anti-angiogenesis therapy for treating several cancer types including breast cancer. Cancer patients with p53-negative or HER2 negative tumors, especially dual p53 HER2-negative tumors or tumors with low levels of apoptosis or high endothelial cell CD31 expression in the tumor samples are more amenable to anti-angiogenesis therapy with bevacizumab. These tumor characteristics provide a diagnostic method for identifying cancer patients amendable to anti-angiogenesis therapy plus chemotherapy for better treatment outcome. | 03-06-2014 |
20140073593 | BRUTON'S TYROSINE KINASE AS ANTI-CANCER DRUG TARGET - Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. | 03-13-2014 |
20140094423 | AQUEOUS HAIR CLEANSING AGENT - An aqueous hair cleansing agent contains a sulfate-type anionic surfactant having a specific structure, an ether carboxylate-type anionic surfactant having a specific structure, and an organic carboxylic acid or salt thereof, thereby has a pH of 1 to 5 at 25° C. when diluted 20-fold with water. | 04-03-2014 |
20140100182 | Nanogel-Mediated Drug Delivery - Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel. | 04-10-2014 |
20140113879 | BLOCK COPOLYMERS FOR STABLE MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 04-24-2014 |
20140128337 | Curcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis - The present invention relates to a curcuminoid for enhancing the clinical efficacy of Docetaxel for the treatment of cancers and metastases. | 05-08-2014 |
20140142056 | METHODS OF TREATING CANCER WITH GLUT INHIBITORS AND OXIDATIVE PHOSPHORYLATION INHIBITORS - Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor. | 05-22-2014 |
20140155343 | TARGETED DELIVERY OF DRUGS, THERAPEUTIC NUCLEIC ACIDS AND FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA INTACT KILLED BACTERIAL CELLS - A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands. | 06-05-2014 |
20140162969 | MICROSPHERES FOR TREATMENT OF BRAIN TUMOURS - There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided. | 06-12-2014 |
20140171382 | METHODS FOR IDENTIFYING AN INCREASED RISK OF ANTHRACYCLINE-RELATED CARDIOTOXICITY - Methods of identifying a subject having an increased risk of developing anthracycline-related cardiotoxicity are provided. Such methods may include isolating a DNA sample from a biological specimen from the subject; genotyping the DNA sample to determine a copy number of a variant allele that increases the risk of developing chemotherapy-induced cardiotoxicity; and identifying the subject as having an increased risk of developing anthracycline-related cardiotoxicity when the copy number is at least one. In some embodiments, the methods may include optimally administering a therapeutically effective dose of a chemotherapy agent or an alternative non-cardiotoxic chemotherapeutic agent to the subject. | 06-19-2014 |
20140194377 | Salts of Isophosphoramide Mustard and Analogs Thereof - Disclosed herein are crystalline compounds of formula (I) | 07-10-2014 |
20140200192 | TOPOISOMERASE 2B AS A PREDICTOR OF SUSCEPTIBILITY TO ANTHRACYCLINE-INDUCED CARDIOTOXICITY - Biomarkers of anthracycline cardiotoxicity are provided. In certain aspects, methods are provided for determining whether a subject will develop cardiotoxicity upon treatment with an anthracycline, such as doxorubicin, by measuring the level of Top2b expression in the subject. In further aspects, methods of a treating a subjects with anthracycline therapeutics and cardioprotective agents are provided. | 07-17-2014 |
20140206634 | Natural Composition to Decrease Effects of a High Fat Diet - The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet. | 07-24-2014 |
20140206635 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG - A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment. | 07-24-2014 |
20140221301 | COMBINATION TREATMENT FOR CANCER - A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a glycylcycline, for example tigecycline in combination with a chemotherapeutic such as daunorubicin or cytarabine. | 08-07-2014 |
20140249097 | Inhibition of HIF-1 activation for Anti-Tumor and Anti-Inflammatory responses - The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a cancer cell, tissue or tumor. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a tumor, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods. | 09-04-2014 |
20140274927 | TNF-Related Biomarkers For Assessing Cancer Cell Response To Treatment With Taxane And/Or Anthracycline Drugs - A method of evaluating response to a taxane drug and/or anthracycline drug, the method comprising measuring a level of a TNF biomarker in a biological sample comprising the cancer cell after contacting the cancer cell with the taxane drug and/or anthracycline drug. | 09-18-2014 |
20140274928 | IDENTIFYING AND TREATING PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER - This disclosure relates generally to the field of prostate cancer and, in particular, methods of identifying and treating patients having castrate resistant prostate cancer. | 09-18-2014 |
20140274929 | Stealth Polymeric Particles For Delivery Of Bioactive Or Diagnostic Agents - The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alkylene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent (the crosslinking agent may be absent in the case of non-crosslinked particles). The present invention is still further directed to a polymer particle comprising a crosslinked copolymer, where the crosslinked copolymer includes structures represented by Formulas (I), (II), and (III), as defined in the specification. Other embodiments of the present invention also include methods of manufacturing polymer particles. | 09-18-2014 |
20140296173 | STABLE NANOCOMPOSITION COMPRISING EPIRUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both; (ii) an active compound selected from the group of epirubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, metal ion and stabilizer/formulating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
20140296174 | SILK-BASED MULTIFUNCTIONAL BIOMEDICAL PLATFORM - The present invention provides a multifunctional platform suitable for biomedical applications. In particular, the invention includes a silk fibroin-based multifunctional device that enables both the sustained delivery of a drug and monitoring of such delivery in vivo. | 10-02-2014 |
20140309183 | Low-Dose Combination Chemotherapy - Disclosed herein are compositions comprising at least two compounds in a therapeutically effective composition for treating cancer. Compositions include a single oral dosage form comprising at least two anti-cancer compounds. Also disclosed herein are methods of making and using such compositions. | 10-16-2014 |
20140309184 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER - Embodiments of the present disclosure relate to methods and compositions for treating a subject with ovarian cancer. Some embodiments include treating a subject with a particular combination of chemotherapeutic agents. | 10-16-2014 |
20140315844 | MULTI-GENE SIGNATURES FOR PREDICTING RESPONSE TO CHEMOTHERAPY OR RISK OF METASTASIS FOR BREAST CANCER - Exemplary embodiments of the invention provide methods and compositions relating to a multi-gene signature, and subsets thereof, for predicting whether an individual with breast cancer will respond to chemotherapy based on expression of the genes in the multi-gene signature, as well as for prognosing risk of breast cancer metastasis. | 10-23-2014 |
20140315845 | HSP90 INHIBITORS WITH MODIFIED TOXICITY - The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders. | 10-23-2014 |
20140323421 | Combination Therapy for Treating Cancer - The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 10-30-2014 |
20140357588 | HIGH-PURITY STEVIOL GLYCOSIDES - Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums. | 12-04-2014 |
20140364387 | METHODS AND SYSTEMS FOR MODULATING HORMONES AND RELATED METHODS, AGENTS AND COMPOSITIONS - Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual. | 12-11-2014 |
20140371165 | Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers - This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same. | 12-18-2014 |
20140378403 | Compounds For Reducing Drug Resistance And Uses Thereof - This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds. | 12-25-2014 |
20140378404 | Treatment of Patients Suffering from Cancer - The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor. | 12-25-2014 |
20150011492 | ANTI-RESTENOSIS COMPOSITIONS AND METHODS - The present invention relates generally to the pathology of restenosis. In particular, provided herein are devices comprising a compound that selectively decreasing smooth muscle cell proliferation without a substantial decrease in endothelial cell proliferation. Also provided are methods of using such devices to treat, prevent, or reduce vascular disease or the likelihood of restenosis following angioplasty. | 01-08-2015 |
20150011493 | COSMETIC USE OF STEVIOL, OF A STEVIOL GLYCOSIDE DERIVATIVE OR OF ONE OF THEIR ISOMERS TO STIMULATE, RESTORE OR REGULATE THE METABOLISM OF THE CELLS OF THE SKIN AND SEMIMUCUS MEMBRANES - The present invention relates to the cosmetic use by external topical route of steviol, of a steviol glycoside derivative or of one of their isomers to stimulate, restore or regulate the metabolism of the cells of the skin. | 01-08-2015 |
20150011494 | THERAPEUTIC CURCUMIN DERIVATIVES - Curcumin analogues and methods are provided for treatment of disease. | 01-08-2015 |
20150018295 | METHOD FOR THE PREPARATION OF TRIGLYCERIDES OF MEDIUM-CHAIN LENGTH FATTY ACIDS - A method is disclosed for the preparation of glycerol esters (triglycerides) of medium-chain length monocarboxylic fatty acids which consists of the reaction of the precursor free fatty acid and glycerol in the presence of a catalyst under partial vacuum. The process preferably uses a metal catalyst such as an oxide or a chloride of tungsten, molybdenum, calcium, zinc, chromium or magnesium. The method of the invention allows the preparation in high yield and high purity (>99.5%) of the final triglyceride. The present method allows the formation of triglycerides without solvent. Are also contemplated, the triglyceride obtained by the method, and the pharmaceutical composition containing the triglyceride as an excipient or as an active ingredient. | 01-15-2015 |
20150025029 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE - A delivery device for a active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders, such as cancer. The delivery device survives for a period of time in the body sufficient to allow for transport and uptake of the delivery device into targeted cells. The degree of crosslinking can provide a desired release profile of the active agent at, near or inside the target cells. The nanoparticles may be made by applying a high shear force in the presence of a cross linker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water. | 01-22-2015 |
20150031641 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA - Gene mutations are associated with the progression of acute myeloid leukemia (AML). The invention relates to methods and systems for evaluating the progression of AML based on these gene mutations. The present invention also relates to methods and compositions for treating AML patients by modulating the expression or activity of certain genes involved in AML progression and/or their encoded proteins. The invention further relates to methods and compositions for determining the responsiveness of an AML patient to induction chemotherapy therapy. | 01-29-2015 |
20150038443 | Transcription Factor Inhibitors and Related Compositions, Formulations and Methods - The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular. | 02-05-2015 |
20150051163 | COMBINATION THERAPY FOR TREATING CANCER - The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 02-19-2015 |
20150065442 | REDUCIBLE SELF-ASSEMBLED MICELLE DRUG DELIVERY SYSTEMS - Reductively degradable micelles comprising poly(-βamino ester)s-g-poly(ethylene glycol) amphiphilic copolymers provided with aromatic phenylbutylamine side groups, suitable for sequestering therein anthrocyclines. The anthrocycline-loaded reductively degradable micelles are useful for therapeutic treatment of cancers. | 03-05-2015 |
20150065443 | EMBELIN-BASED DELIVERY SYSTEM FOR WATER-INSOLUBLE ACTIVE AGENTS - A composition having a structure of: | 03-05-2015 |
20150065444 | METHOD FOR ENHANCING EFFICACY AND SELECTIVITY OF CANCER CELL KILLING BY DNA DAMAGING AGENTS - The invention relates to the treatment of cancer using DNA damaging agents. The invention provides methods for treating a mammal with cancer, the method comprising inhibiting in the mammal acidic residue methyltransferase (Arm1) in combination with administering to the mammal a DNA damaging agent. The invention further provides pharmaceutical formulations comprising an inhibitor of acidic residue methyltransferase (Arm1) and a DNA damaging agent. | 03-05-2015 |
20150072946 | PROCESS FOR THE PREPARATION OF POLYSACCHARIDE NANOPARTICLES - A process for the preparation of nanoparticles from polysaccharides and derivatives thereof, by their specific partial oxidation to produce aldehyde groups and attachment of compounds with amino or other group with the R—NH2 bond which react with aldehyde groups, and a nanoparticle produced by such process. | 03-12-2015 |
20150080328 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DISORDERS - The present invention relates to compounds and compositions and their application as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject. | 03-19-2015 |
20150087609 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE - The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as CDM-Hs, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by introducing cytotoxic moieties to gp120-expressing cells, thereby causing cell death and preventing cell infection and spread of HIV. It is shown that CDM-Hs bind to gp120 and gp-120 expressing cells competitively with CD4, and these compounds cause cell death of HIV-infected cells, thereby decreasing viral infectivity. Compounds and methods are described herein. | 03-26-2015 |
20150094274 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 04-02-2015 |
20150141359 | Controlled Release Formulations for the Delivery of HIF-1 Inhibitors - Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD. | 05-21-2015 |
20150148307 | METHODS AND COMPOSITIONS FOR THE PROGNOSIS AND TREATMENT OF RELAPSED LEUKEMIA - The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject. | 05-28-2015 |
20150299798 | METHOD FOR CLASSIFICATION OF LIVER SAMPLES AND DIAGNOSIS OF FOCAL NODULE DYSPLASIA, HEPATOCELLULAR ADENOMA, AND HEPATOCELLULAR CARCINOMA - The present invention relates to the technical field of liver diseases, their classification and diagnosis. It provides a new method for classifying a liver sample between non-hepatocellular sample; hepatocellular carcinoma (HCC) sample with further classification into one of subgroups G1 to G6; focal nodule dysplasia (FNH) sample; hepatocellular adenoma (HCA) sample with further classification into HNF1A mutated HCA, inflammatory HCA, β catenin mutated HCA or other HCA sample; and other benign liver sample, based on determination in vitro of genes expression profiles and analysis of the expression profile using algorithms calibrated with reference samples. The invention also provides kits for the classification of liver samples, and methods of treatment of liver disease in a subject based on a preliminary classification of a liver sample of said subject. | 10-22-2015 |
20150313925 | COMBINATION OF COMPOUNDS DERIVED FROM GALLIC ACID FOR THE TREATMENT OF CANCER - The invention relates to a combination of compounds derived from gallic acid, with an antitumoral and antimetastatic activity via a mechanism that involves the induction of apoptosis and the immunogenic death of the tumour cells and the subsequent activation of the specific immune response. The invention also relates to a composition containing a combination of derivatives of gallic acid and pharmaceutically acceptable excipients for the production of useful medicaments in the treatment of cancer. The invention further relates to the use of said composition in a coadjuvant in conventional chemotherapy, reducing the doses of chemptherapeutic agents used in the treatment of cancer. | 11-05-2015 |
20150322521 | METHODS TO DIAGNOSE AND TREAT MULLERIAN ADENOSARCOMA - Methods for diagnosing and treating Müllerian Adenosarcoma that include detecting the presence of one or more of a mutation in an ATRX gene, and/or a Copy Number Variation (CNV) in a MYBL1, MDM2, HMGA2, and/or CDK4 gene. | 11-12-2015 |
20150328218 | Reduction Of Toxicity Of Multi-Targeting Antifolates - The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed. | 11-19-2015 |
20150329512 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER - The present invention is related to a method and pharmaceutical composition for treating lung cancer. The pharmaceutical composition comprises an effective amount of 16-hydroxy-cleroda-3,13-dine-15,16-olide as active ingredient, and a pharmaceutically acceptable carrier. The present method and pharmaceutical composition provides good efficacy in treating lung cancer even for drug-resistance patient. The present invention also establishes an animal model bearing human lung cancer, which provides a better drug screening platform for the research. | 11-19-2015 |
20150342975 | ANTHRACYCLINE FORMULATIONS - The invention relates to reconstituted formulations comprising an anthracycline compound, ethanol, and water. The invention also relates to injectable compositions comprising the reconstituted formulation and Lactated Ringer's solution. Additionally, the invention relates to methods of using the formulations and compositions. | 12-03-2015 |
20150366975 | THERMOSENSITIVE INJECTABLE HYDROGEL FOR DRUG DELIVERY - The invention develops a developed a thermosensitive injectable hydrogel based on HA and a copolymer of polyethylene oxide (PEO) and polypropylene oxide (PPO), which has a gel formation temperature from 30° C. to 37° C. The thermosensitive injectable hydrogel of the invention provides a potential drug delivery system that can increase therapeutic efficacy of the drug. | 12-24-2015 |
20160003848 | METHOD FOR PREDICTING THERAPY EFFICACY USING NUCLEOSOME STRUCTURE BIOMARKERS - The invention relates to a method for predicting the efficacy of therapeutic treatments, particularly neoadjuvant cancer treatments, using the levels of cell free nucleosome structures. | 01-07-2016 |
20160008481 | SELF-ASSEMBLING COMPLEX FOR TARGETING CHEMICAL AGENTS TO CELLS | 01-14-2016 |
20160022751 | NOVEL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND IMPROVING COGNITIVE FUNCTION OF ALZHEIMER'S PATIENTS - The present invention relates to a pharmaceutical composition for treating Alzheimer's disease and improving cognitive function of Alzheimer's patients, and more specifically for pharmaceutical composition for treating Alzheimer's disease and improving cognitive function of Alzheimer's patients comprising ginsenoside complex prepared by sequential fraction of steam-dried unripened ginseng berries using solvents and used thereof. | 01-28-2016 |
20160038521 | THERAPEUTIC METHODS - Certain embodiments of the present invention provide a method for treating or preventing juvenile neuronal ceroid lipofuscinosis (JNCL) in an animal comprising administering CBX, GRA, or GZA to the animal. | 02-11-2016 |
20160045531 | COMBINATION THERAPY FOR TREATING CANCER - The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 02-18-2016 |
20160045532 | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY - Disclosed herein are methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. Example disclosed methods reduce cardiotoxicity of a chemotherapeutic agent. Also disclosed are methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the chemotherapeutic agent. | 02-18-2016 |
20160068558 | ANTICANCER AGENTS OF THE ANTHRACYCLIN FAMILY - Anthracyclin compounds of the general structure: | 03-10-2016 |
20160074424 | Compositions for Use in Restoring Muscle Glycogen and/or Muscle Mass - The present invention relates to compositions comprising a steviol glycoside for use in restoring muscle glycogen by increasing the rate of glycogen re-synthesis in muscles that are depleted in glycogen due to exhaustive exercise and/or for use in treatment of muscle mass by increasing the rate of protein synthesis in muscles that are depleted in protein mass. | 03-17-2016 |
20160075730 | NEW MORPHOLINYL ANTHRACYCLINE DERIVATIVES - The present invention relates to new morpholinyl anthracycline derivatives which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them. | 03-17-2016 |
20160089388 | CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER - The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolvtically or enzymaticaily in the body of the patient in a pH-dependent manner. | 03-31-2016 |
20160095873 | COMPOSITIONS AND METHODS FOR TRANSIENT UP-REGULATION OF MYC IN B-CELL LYMPHOMAS FOR ENHANCING P53 INDEPENDENT APOPTOTIC RESPONSES TO CHEMOTHERAPY - Compositions and methods useful for the treatment of cancer, particularly lymphoma, are disclosed. | 04-07-2016 |
20160106743 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compositions of Formula I and an optional anticancer drug. Also disclosed herein are methods of treating or preventing cancer using the same. | 04-21-2016 |
20160114046 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF - The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases. | 04-28-2016 |
20160128999 | MASITINIB FOR TREATING HEPATIC CANCER - A method for treating hepatic cancer in a subject in need thereof, which includes the administration to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent. | 05-12-2016 |
20160137685 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES - The invention provides phosphoramidate prodrugs for targeting and treating liver disease, including liver cancer, hepatocellular carcinoma, and hepatitis. | 05-19-2016 |
20160143937 | METHODS OF USING CLEAVABLE DRUG CONJUGATES AND COMPOSITIONS THEREOF - Methods of synthesizing and using base-labile drug conjugates and compositions thereof are disclosed. | 05-26-2016 |
20160144031 | Photo-Responsive Compounds - The presently-disclosed subject matter provides photo-responsive compounds and methods of use thereof. The photo-responsive compounds comprise a photolabile molecule and a fluorophore appended to the photolabile molecule. The presently-disclosed subject matter further relates to a drug delivery system that uses red blood cells to deliver photo-responsive compounds for the treatment of disease. | 05-26-2016 |
20160151362 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | 06-02-2016 |
20160165938 | STEVIA COMPOSITION | 06-16-2016 |
20160166549 | BCL6 INHIBITORS AS ANTICANCER AGENTS | 06-16-2016 |
20160199345 | USE OF WILFORLIDE A FOR OVERCOMING CHEMOTHERAPY RESISTANCE | 07-14-2016 |
20160375021 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 12-29-2016 |
20160377621 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS - Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin. | 12-29-2016 |
20180021331 | HDAC1,2 INHIBITORS AND METHODS OF USING THE SAME | 01-25-2018 |
20180021456 | SELF-ASSEMBLED TARGETED INCLUSION COMPLEXES FOR DRUG DELIVERY | 01-25-2018 |
20180022700 | COMPOUND CONTAINING INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | 01-25-2018 |
20190142946 | RADIOPAQUE POLYMERS | 05-16-2019 |
20220133760 | IDENTIFICATION AND TREATMENT OF T-CELL EPITOPES OF SHORT H2A ONCOHISTONES - The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin. | 05-05-2022 |
20220133761 | NEUTROPHIL APOPTOSIS INDUCED BY NANOPARTICLES FOR TREATING INFLAMMATORY DISEASES - Disclosed are methods and compounds to selectively target the apoptosis pathway in proinflammatory neutrophils using Topoisomerase nanoparticles (NPs). The design of the disclosed nanoparticles (NPs) allows controlled release of DOX inside neutrophils, thus avoiding systemic toxicity. One such beneficial method for treating a subject neutrophil-inflammatory infection or tissue injury response includes administering a topoisomerase-conjugated albumin protein nanoparticles (NPs) composition to the subject, wherein the composition includes an effective amount so as to induce apoptosis of neutrophils, wherein the neutrophil induced inflammatory response is lower following the administration of the composition. | 05-05-2022 |